Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry

Ian N H White, Elizabeth A. Martin, Robert J. Mauthe, John S. Vogel, Ken W Turteltaub, Lewis L. Smith

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Tamoxifen, widely used as adjuvant therapy in the treatment of breast cancer, is now undergoing trials as a cancer chemopreventative agent. Previous work has shown an association between 32P-postlabelled adducts in rat liver DNA and the development of liver tumours. With the use of accelerator mass spectrometry, [14C]tamoxifen was shown to bind to liver DNA of female rats in a dose-dependent manner and was linear over 0.1-1 mg/kg, compatible with the therapeutic dose used in women (20 mg/person per day). Radiolabel could also be detected in extrahepatic organs, including reproductive and GI-tract, where levels were about 18 and 46%, respectively those seen in liver. Following enzymatic hydrolysis of liver DNA, normal nucleotides by HPLC showed < 2% incorporation of the [14C]radioactivity while > 80% appeared as non-polar products. In contrast, when animals were given an equivalent dose of [14C]toremifene, binding to DNA was an order of magnitude lower than that seen with tamoxifen and no evidence of non-polar adducted nucleotides following HPLC. However, in vitro, using human, rat or mouse liver microsomal preparations, NADPH-dependent binding of both toremifene and tamoxifen to calf thymus DNA could be demonstrated, suggesting that under favourable circumstances toremifene is capable of undergoing conversion to reactive intermediates.

Original languageEnglish (US)
Pages (from-to)149-160
Number of pages12
JournalChemico-Biological Interactions
Volume106
Issue number2
DOIs
StatePublished - Sep 12 1997
Externally publishedYes

Fingerprint

Toremifene
Tamoxifen
Liver
Particle accelerators
Mass spectrometry
Rats
Mass Spectrometry
DNA
Nucleotides
High Pressure Liquid Chromatography
Enzymatic hydrolysis
NADP
Gastrointestinal Tract
Tumors
Neoplasms
Animals
Hydrolysis
Therapeutics
Association reactions
Breast Neoplasms

Keywords

  • P- postlabelling
  • Accelerator mass spectrometry
  • DNA binding
  • Tamoxifen
  • Toremifene

ASJC Scopus subject areas

  • Toxicology

Cite this

Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. / White, Ian N H; Martin, Elizabeth A.; Mauthe, Robert J.; Vogel, John S.; Turteltaub, Ken W; Smith, Lewis L.

In: Chemico-Biological Interactions, Vol. 106, No. 2, 12.09.1997, p. 149-160.

Research output: Contribution to journalArticle

White, Ian N H ; Martin, Elizabeth A. ; Mauthe, Robert J. ; Vogel, John S. ; Turteltaub, Ken W ; Smith, Lewis L. / Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. In: Chemico-Biological Interactions. 1997 ; Vol. 106, No. 2. pp. 149-160.
@article{0198f2d9463349e6a9f8374f72be27c2,
title = "Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry",
abstract = "Tamoxifen, widely used as adjuvant therapy in the treatment of breast cancer, is now undergoing trials as a cancer chemopreventative agent. Previous work has shown an association between 32P-postlabelled adducts in rat liver DNA and the development of liver tumours. With the use of accelerator mass spectrometry, [14C]tamoxifen was shown to bind to liver DNA of female rats in a dose-dependent manner and was linear over 0.1-1 mg/kg, compatible with the therapeutic dose used in women (20 mg/person per day). Radiolabel could also be detected in extrahepatic organs, including reproductive and GI-tract, where levels were about 18 and 46{\%}, respectively those seen in liver. Following enzymatic hydrolysis of liver DNA, normal nucleotides by HPLC showed < 2{\%} incorporation of the [14C]radioactivity while > 80{\%} appeared as non-polar products. In contrast, when animals were given an equivalent dose of [14C]toremifene, binding to DNA was an order of magnitude lower than that seen with tamoxifen and no evidence of non-polar adducted nucleotides following HPLC. However, in vitro, using human, rat or mouse liver microsomal preparations, NADPH-dependent binding of both toremifene and tamoxifen to calf thymus DNA could be demonstrated, suggesting that under favourable circumstances toremifene is capable of undergoing conversion to reactive intermediates.",
keywords = "P- postlabelling, Accelerator mass spectrometry, DNA binding, Tamoxifen, Toremifene",
author = "White, {Ian N H} and Martin, {Elizabeth A.} and Mauthe, {Robert J.} and Vogel, {John S.} and Turteltaub, {Ken W} and Smith, {Lewis L.}",
year = "1997",
month = "9",
day = "12",
doi = "10.1016/S0009-2797(97)00063-X",
language = "English (US)",
volume = "106",
pages = "149--160",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry

AU - White, Ian N H

AU - Martin, Elizabeth A.

AU - Mauthe, Robert J.

AU - Vogel, John S.

AU - Turteltaub, Ken W

AU - Smith, Lewis L.

PY - 1997/9/12

Y1 - 1997/9/12

N2 - Tamoxifen, widely used as adjuvant therapy in the treatment of breast cancer, is now undergoing trials as a cancer chemopreventative agent. Previous work has shown an association between 32P-postlabelled adducts in rat liver DNA and the development of liver tumours. With the use of accelerator mass spectrometry, [14C]tamoxifen was shown to bind to liver DNA of female rats in a dose-dependent manner and was linear over 0.1-1 mg/kg, compatible with the therapeutic dose used in women (20 mg/person per day). Radiolabel could also be detected in extrahepatic organs, including reproductive and GI-tract, where levels were about 18 and 46%, respectively those seen in liver. Following enzymatic hydrolysis of liver DNA, normal nucleotides by HPLC showed < 2% incorporation of the [14C]radioactivity while > 80% appeared as non-polar products. In contrast, when animals were given an equivalent dose of [14C]toremifene, binding to DNA was an order of magnitude lower than that seen with tamoxifen and no evidence of non-polar adducted nucleotides following HPLC. However, in vitro, using human, rat or mouse liver microsomal preparations, NADPH-dependent binding of both toremifene and tamoxifen to calf thymus DNA could be demonstrated, suggesting that under favourable circumstances toremifene is capable of undergoing conversion to reactive intermediates.

AB - Tamoxifen, widely used as adjuvant therapy in the treatment of breast cancer, is now undergoing trials as a cancer chemopreventative agent. Previous work has shown an association between 32P-postlabelled adducts in rat liver DNA and the development of liver tumours. With the use of accelerator mass spectrometry, [14C]tamoxifen was shown to bind to liver DNA of female rats in a dose-dependent manner and was linear over 0.1-1 mg/kg, compatible with the therapeutic dose used in women (20 mg/person per day). Radiolabel could also be detected in extrahepatic organs, including reproductive and GI-tract, where levels were about 18 and 46%, respectively those seen in liver. Following enzymatic hydrolysis of liver DNA, normal nucleotides by HPLC showed < 2% incorporation of the [14C]radioactivity while > 80% appeared as non-polar products. In contrast, when animals were given an equivalent dose of [14C]toremifene, binding to DNA was an order of magnitude lower than that seen with tamoxifen and no evidence of non-polar adducted nucleotides following HPLC. However, in vitro, using human, rat or mouse liver microsomal preparations, NADPH-dependent binding of both toremifene and tamoxifen to calf thymus DNA could be demonstrated, suggesting that under favourable circumstances toremifene is capable of undergoing conversion to reactive intermediates.

KW - P- postlabelling

KW - Accelerator mass spectrometry

KW - DNA binding

KW - Tamoxifen

KW - Toremifene

UR - http://www.scopus.com/inward/record.url?scp=0030613674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030613674&partnerID=8YFLogxK

U2 - 10.1016/S0009-2797(97)00063-X

DO - 10.1016/S0009-2797(97)00063-X

M3 - Article

C2 - 9366900

AN - SCOPUS:0030613674

VL - 106

SP - 149

EP - 160

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 2

ER -